Third-Party Screening and Monitoring Are Critical for Health Care and Life Science Companies

Published date29 August 2019
Subject MatterHealth Care Providers,Life Sciences,Enforcement Actions,Corporate Liability,Pharmaceutical Industry,Screening Procedures,FCPA,SEC,UK Bribery Act,Corporate Misconduct,Risk Mitigation
AuthorMimi Yang,David Chen,Karen Oddo,Yujin Liu
Law FirmRopes & Gray LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT